# **Oxurion Receives Transparency Notification from Negma Group**

**Leuven, BELGIUM, Boston, MA, US – December 21, 2022 – 7.30 PM CET** Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation<sup>1</sup> it has received transparency notifications as follows:

Oxurion received transparency notification on December 21 from Negma Group Ltd. indicating that as of December 15, it held 4,000,000 shares of the then outstanding 411,071,559 shares, and therefore crossed below the lowest threshold (3%) by virtue of disposal of voting securities. See Annex 1

### **About Oxurion**

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

#### Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

#### For further information please contact:

Tom Graney	Conway Communications
Chief Executive Officer	Beth Kurth
Tel: +32 16 75 13 10	bkurth@conwaycommsir.com
tom.graney@oxurion.com	
Michael Dillen	ICR Westwicke
Chief Business Officer	Christopher Brinzey
Tel: +32 16 75 13 10	Tel: +1 617 835 9304
michael.dillen@oxurion.com	Chris.Brinzey@westwicke.com

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

## ANNEX 1


	L SERVICES AND AUTHORITY		Transpare Form TR-1 E PART I	ency notific BE	ation		
1) Status of the notification							
	Final						
2) Issuer							
Nam Identification numbe	OXURION 0881-620-924						
3) Reason for the notification	20.						
	Acquisition or disposal of voting		ls				-
	Downward crossing of the lowes	t threshold					4
4) Notification by							
	A parent undertaking or a control	ling person					+
5) Persons subject to the n	otification requirement						
	Name	•		Address (for le	gal entities)		
	Elaf Gassam						-
	Negma Group Investment Ltd.			Brookfield Place, DIFC, Road Town, Tortola, V		100	14
	Negma Group Ltd.		islands)	rous rour, rouse, v	or the particular and		*
6) Persons that dispose of	voting rights (only to be file	d in if art. 7 of the Law	vapples)				
	1 Control -			Address (for le			
	Name	4.		Autoree from is	gai aticicas)		
7) Date on which the thresh		nformation in part II o s 6 and 8	oncerning the	Part II			
The of which we used	iona is crossed						
		15/12/2022	(DDIMM/YYYY)				
8) Threshold that is crosse	<u>d</u> (in %)						
	5	3					
	If the holding has fallen below	the lowest threshold,	you have the option	n of not entering any n	umbers in Section	n 10	
9) Denominator							
		411,071,559					
	Please enter the denominator		fa				
10) Notified details							
A) Voting rights	Previous notifi	oation		After the tra	nsaotion		
	# of voling ri			ing rights		ting rights	
Holders of voting rights	10	2	Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities	_
Elaf Gassam							
	0		0		0.00%		22
Negma Group Investment Ltd.	0		0		0.00%		
1					11-12-15		·* •

	TOTAL	4,000,000	 0.87%	
0	Start with "groups" of holders. Add sublotals with For groups, start with the utilimate controlling natur The totals, subtotals and % will be updated once yo		are "alone".	

) Equivalent financial Instruments	After the transaction						
Holders of equivalent finanoial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Sottlament	
				-			-
	TOTAL	-0					
0	The socials will be updated once you have olioke	d on «CALCULATE»					
	TOTAL (A & B)			# of voting rights	% of voting rights		

CALCULATE 4,000,000 0.87%

11) Full chain of controlled undertakings through which the holding is effectively held, # applicable



Done at Dubal, United Arab Emirates					
On	21/12/2022	(ררריאושס)			
me & capacity Elaf Gassam, Director			Signature	5-1	